#biotech
#biotech

[ follow ]

Bay Area biotech company, once worth $1.2 billion, lays off almost entire staff

Cargo Therapeutics is laying off nearly all its employees after ceasing drug development due to trial failures, marking a major decline for the biotech firm.

Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views

Stocks of major vaccine companies fell after FDA official Dr. Peter Marks resigned amidst conflicts with HHS Secretary RFK Jr. over vaccine misinformation.

Stocks making the biggest moves premarket: Amazon, Apple, Atlassian and more

Amazon reports strong earnings driven by cloud and advertising growth.

Atlassian sees major stock surge after exceeding earnings expectations.

Intel beats earnings and revenue estimates, boosting investor confidence.

Abbott's stock rises after jury ruling in a liability case.

Warren Buffett Back for More, Plus Big Insider Buying at Biotechs Too

Insider buying signals confidence in stock performance, especially during uncertain market conditions.

Berkshire Hathaway continues to show strong investment activity in key sectors, such as media and biotech.

Bay Area biotech firm guts staff, shuts trial after dangerous side effects

Cargo Therapeutics halts a clinical trial and lays off half its workforce due to poor results and the need to conserve cash.

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Eli Lilly's stock has risen dramatically, but future estimates depend on revenue projections and strategic partnerships.

Bay Area biotech company, once worth $1.2 billion, lays off almost entire staff

Cargo Therapeutics is laying off nearly all its employees after ceasing drug development due to trial failures, marking a major decline for the biotech firm.

Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views

Stocks of major vaccine companies fell after FDA official Dr. Peter Marks resigned amidst conflicts with HHS Secretary RFK Jr. over vaccine misinformation.

Stocks making the biggest moves premarket: Amazon, Apple, Atlassian and more

Amazon reports strong earnings driven by cloud and advertising growth.

Atlassian sees major stock surge after exceeding earnings expectations.

Intel beats earnings and revenue estimates, boosting investor confidence.

Abbott's stock rises after jury ruling in a liability case.

Warren Buffett Back for More, Plus Big Insider Buying at Biotechs Too

Insider buying signals confidence in stock performance, especially during uncertain market conditions.

Berkshire Hathaway continues to show strong investment activity in key sectors, such as media and biotech.

Bay Area biotech firm guts staff, shuts trial after dangerous side effects

Cargo Therapeutics halts a clinical trial and lays off half its workforce due to poor results and the need to conserve cash.

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Eli Lilly's stock has risen dramatically, but future estimates depend on revenue projections and strategic partnerships.

morestock-market

#23andme

23andMe is filing for bankruptcy. Here's what it means for your genetic data

23andMe has filed for bankruptcy amidst financial struggles and concerns over user data privacy.

Bay Area tech CEO resigns to bid for own flailing company

23andMe declared bankruptcy in Missouri court, reflecting its financial turmoil and struggles to maintain operations after a major data breach.

What went wrong at 23andMe? Why the genetic-data giant risks collapse

23andMe faces severe struggles, raising concerns about consumer genetic data and the future of the industry.

23andMe is filing for bankruptcy. Here's what it means for your genetic data

23andMe has filed for bankruptcy amidst financial struggles and concerns over user data privacy.

Bay Area tech CEO resigns to bid for own flailing company

23andMe declared bankruptcy in Missouri court, reflecting its financial turmoil and struggles to maintain operations after a major data breach.

What went wrong at 23andMe? Why the genetic-data giant risks collapse

23andMe faces severe struggles, raising concerns about consumer genetic data and the future of the industry.

more23andme

#innovation

#NYCtech Week in Review: 8/18/24 - 8/24/24

NYC Tech is witnessing significant startup funding, indicating a robust entrepreneurial ecosystem.

#NYCtech Week in Review: 5/26/24 - 6/1/24

Diverse NYC startup fundings and events include Gameto's $33M biotech raise, Authentic Insurance's $11M, Matter Bio's $7M, and Clasp's $6.4M funding.

Unleased lab space. Plunging valuations. Layoffs. In Massachusetts, the biotech slump is taking its toll.

The biotech sector faces significant challenges in 2023, undermining hopes for a rebound despite scientific advancements and interest rate drops.

Prolific Machines, with a $55M Series B, shines 'light' on a better way to grow lab proteins for food and medicine | TechCrunch

Prolific Machines has developed a bioreactor using light to control cell growth, aiming to revolutionize manufacturing of cultivated meat and medicine.

Visibuilt Raises 1.3 Million to Transform Asphalt Production with Mycelium

Visibuilt raises €1.3 million to develop visiBIT, a sustainable binder that could replace traditional bitumen in asphalt production and reduce CO2 emissions.

Many scientists are neurodivergent. Architects are finally starting to build labs designed for them

Traditional lab designs may inhibit research by not accommodating the diverse needs of neurodivergent scientists.

#NYCtech Week in Review: 8/18/24 - 8/24/24

NYC Tech is witnessing significant startup funding, indicating a robust entrepreneurial ecosystem.

#NYCtech Week in Review: 5/26/24 - 6/1/24

Diverse NYC startup fundings and events include Gameto's $33M biotech raise, Authentic Insurance's $11M, Matter Bio's $7M, and Clasp's $6.4M funding.

Unleased lab space. Plunging valuations. Layoffs. In Massachusetts, the biotech slump is taking its toll.

The biotech sector faces significant challenges in 2023, undermining hopes for a rebound despite scientific advancements and interest rate drops.

Prolific Machines, with a $55M Series B, shines 'light' on a better way to grow lab proteins for food and medicine | TechCrunch

Prolific Machines has developed a bioreactor using light to control cell growth, aiming to revolutionize manufacturing of cultivated meat and medicine.

Visibuilt Raises 1.3 Million to Transform Asphalt Production with Mycelium

Visibuilt raises €1.3 million to develop visiBIT, a sustainable binder that could replace traditional bitumen in asphalt production and reduce CO2 emissions.

Many scientists are neurodivergent. Architects are finally starting to build labs designed for them

Traditional lab designs may inhibit research by not accommodating the diverse needs of neurodivergent scientists.

moreinnovation

#layoffs

Bay Area biotech company once worth $2B guts staff, departing execs get $600K

Sutro Biopharma faces drastic staff reductions and shifts in leadership due to ongoing financial losses.

Bay Area biotech giant to lay off hundreds after $1.8 billion loss

Bio-Rad Laboratories is laying off over 350 employees, primarily in the U.S., due to financial losses and challenging market conditions.

Bay Area biotech firm once worth $13B lays off all but 15 workers

Allakos announces failure of pivotal clinical trial for chronic hives drug AK006, resulting in a 75% staff layoff.

Calif. biotech company once worth $476M lays off every remaining employee

Viracta Therapeutics has ceased operations and laid off all employees after failing to secure funding and ultimately shut down its drug development program.

Bay Area biotech company lays off staff over sudden Trump administration order

Robert F. Kennedy Jr.'s role as Secretary of Health and Human Services is triggering layoffs in the Bay Area biotech sector due to regulatory changes.

Struggling Bay Area biotech firm, once worth $1B, lays off almost entire staff

Kronos Bio is undergoing major layoffs and has discontinued its only clinical drug due to adverse effects.

Bay Area biotech company once worth $2B guts staff, departing execs get $600K

Sutro Biopharma faces drastic staff reductions and shifts in leadership due to ongoing financial losses.

Bay Area biotech giant to lay off hundreds after $1.8 billion loss

Bio-Rad Laboratories is laying off over 350 employees, primarily in the U.S., due to financial losses and challenging market conditions.

Bay Area biotech firm once worth $13B lays off all but 15 workers

Allakos announces failure of pivotal clinical trial for chronic hives drug AK006, resulting in a 75% staff layoff.

Calif. biotech company once worth $476M lays off every remaining employee

Viracta Therapeutics has ceased operations and laid off all employees after failing to secure funding and ultimately shut down its drug development program.

Bay Area biotech company lays off staff over sudden Trump administration order

Robert F. Kennedy Jr.'s role as Secretary of Health and Human Services is triggering layoffs in the Bay Area biotech sector due to regulatory changes.

Struggling Bay Area biotech firm, once worth $1B, lays off almost entire staff

Kronos Bio is undergoing major layoffs and has discontinued its only clinical drug due to adverse effects.

morelayoffs

#investment

Cradle builds out its protein-design AI platform (and wet lab) with $73M in new funding | TechCrunch

AI is rapidly transforming biotech, with companies like Cradle leading the charge in protein design and development.

Hollywood's Olivia Wilde launches a VC firm | TechCrunch

Olivia Wilde launches Proximity Ventures, targeting early and growth-stage investments in consumer and enterprise sectors.

Biotech startup Cradle raises $73 million in investment round

Cradle raised $73 million to enhance its AI platform for protein development, aiming to optimize DNA sequences and scale operations.

AstraZeneca to invest $2.5bn in drugs research and manfacturing in Beijing

AstraZeneca invests $2.5 billion in Beijing to bolster research, moving past recent controversies while collaborating with local biotech firms.

Dutch immunotherapy company Pan Cancer T bags 4.2M - Silicon Canals

Rotterdam-based Pan Cancer T secured €4.25M in seed extension, advancing T cell therapies for solid cancers, with support from new and existing investors.

Cradle builds out its protein-design AI platform (and wet lab) with $73M in new funding | TechCrunch

AI is rapidly transforming biotech, with companies like Cradle leading the charge in protein design and development.

Hollywood's Olivia Wilde launches a VC firm | TechCrunch

Olivia Wilde launches Proximity Ventures, targeting early and growth-stage investments in consumer and enterprise sectors.

Biotech startup Cradle raises $73 million in investment round

Cradle raised $73 million to enhance its AI platform for protein development, aiming to optimize DNA sequences and scale operations.

AstraZeneca to invest $2.5bn in drugs research and manfacturing in Beijing

AstraZeneca invests $2.5 billion in Beijing to bolster research, moving past recent controversies while collaborating with local biotech firms.

Dutch immunotherapy company Pan Cancer T bags 4.2M - Silicon Canals

Rotterdam-based Pan Cancer T secured €4.25M in seed extension, advancing T cell therapies for solid cancers, with support from new and existing investors.

moreinvestment

Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks

Alex Denner's Sarissa Capital Management holds eight stocks, with three making up 75% of its portfolio.

#funding

Dutch biotech startup Cortalix secures 1M

Cortalix, a Dutch biotech startup, raised €1M to advance its nanobody technology for PET imaging and cancer therapies.

NIH funding uncertainty spurs new biotech venture fund | TechCrunch

The Trump administration's funding restrictions could limit grants to biotech startups, prompting the launch of a new pre-seed venture fund.

How Can Startups Navigate the Difficult Funding Environment - MedCity News

The current funding environment is challenging for startups and investors, forcing a need for creative capital solutions.

Barcelona's Zymvol secures 3M: CEO Maria Fatima Lucas on democratising enzyme development, market expansion, and more - Silicon Canals

Zymvol secured €3M in seed funding to enhance its enzyme engineering technology and expand its market presence.

Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy

Verdiva has raised $410 million to develop oral drugs for obesity, challenging established players by addressing unmet medical needs in weight loss.

Triveni Bio Raises $115M Series B Financing to Advance Antibody Treatments for I&I Disorders

Triveni Bio Inc. raised $115 million to accelerate its antibody therapies for immune and inflammatory disorders, focusing on novel pathways and advanced treatment efficacy.

Dutch biotech startup Cortalix secures 1M

Cortalix, a Dutch biotech startup, raised €1M to advance its nanobody technology for PET imaging and cancer therapies.

NIH funding uncertainty spurs new biotech venture fund | TechCrunch

The Trump administration's funding restrictions could limit grants to biotech startups, prompting the launch of a new pre-seed venture fund.

How Can Startups Navigate the Difficult Funding Environment - MedCity News

The current funding environment is challenging for startups and investors, forcing a need for creative capital solutions.

Barcelona's Zymvol secures 3M: CEO Maria Fatima Lucas on democratising enzyme development, market expansion, and more - Silicon Canals

Zymvol secured €3M in seed funding to enhance its enzyme engineering technology and expand its market presence.

Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy

Verdiva has raised $410 million to develop oral drugs for obesity, challenging established players by addressing unmet medical needs in weight loss.

Triveni Bio Raises $115M Series B Financing to Advance Antibody Treatments for I&I Disorders

Triveni Bio Inc. raised $115 million to accelerate its antibody therapies for immune and inflammatory disorders, focusing on novel pathways and advanced treatment efficacy.

morefunding

Amsterdam's biotech firm Photanol files for bankruptcy

Photanol BV has filed for bankruptcy due to financing challenges, halting its promising CO2-to-chemical technology.

#market-trends

Biotechs Highlight 6 Stocks Insiders Are Buying Now

Insider buying in biotech companies signals potential growth for investors amid market uncertainty.

Prediction: This Will Be the Best-Performing Growth Stock Over the Next 5 Years

Investors are shifting focus to growth stocks as interest rates decline, with a mix of established companies and biotech options leading the pack.

Biotechs Highlight 6 Stocks Insiders Are Buying Now

Insider buying in biotech companies signals potential growth for investors amid market uncertainty.

Prediction: This Will Be the Best-Performing Growth Stock Over the Next 5 Years

Investors are shifting focus to growth stocks as interest rates decline, with a mix of established companies and biotech options leading the pack.

moremarket-trends

#therapeutics

How automotive exec Crystal Brown founded CircNova, an AI drug discovery biotech | TechCrunch

CircNova raises $3.3 million to develop AI-driven therapies targeting circular RNA for previously untreatable conditions.

'Where we are today in biology AI is similar to GPT in 2020': An interview with the CEO of Africa's biggest AI startup | TechCrunch

Instadeep has advanced its AI capabilities significantly while aligning with BioNTech's therapeutic goals post-acquisition.

How automotive exec Crystal Brown founded CircNova, an AI drug discovery biotech | TechCrunch

CircNova raises $3.3 million to develop AI-driven therapies targeting circular RNA for previously untreatable conditions.

'Where we are today in biology AI is similar to GPT in 2020': An interview with the CEO of Africa's biggest AI startup | TechCrunch

Instadeep has advanced its AI capabilities significantly while aligning with BioNTech's therapeutic goals post-acquisition.

moretherapeutics

#gene-editing

Bay Area biotech company that raised $66 million shuts down

Spotlight Therapeutics has closed down due to inadequate research outcomes and ongoing financial challenges.

Leiden-based biotech company ProQR bags 7.7M

ProQR Therapeutics secures $8.1 million to advance RNA therapies for Rett syndrome, focusing on MECP2 gene mutations.

The Axiomer platform enables precise RNA edits, offering hope for treating genetic disorders.

Bay Area biotech company that raised $66 million shuts down

Spotlight Therapeutics has closed down due to inadequate research outcomes and ongoing financial challenges.

Leiden-based biotech company ProQR bags 7.7M

ProQR Therapeutics secures $8.1 million to advance RNA therapies for Rett syndrome, focusing on MECP2 gene mutations.

The Axiomer platform enables precise RNA edits, offering hope for treating genetic disorders.

moregene-editing

Skinny jabs' are turning slimmers teetotal and drinks companies are feeling the loss

Weight loss medications like Wegovy significantly reduce alcohol cravings, impacting consumer behavior.

The rise of weight loss drugs could threaten the beverage sector, especially alcohol companies.

Bay Area biotech firm once worth billions guts staff with 73% layoff

IGM Biosciences lays off 73% of staff due to poor clinical study results and aims to preserve cash amid ongoing research challenges.

Jill Biden Arriving In San Francisco, Speaking Tuesday at JP Morgan Conference

The JP Morgan Healthcare Conference, now Fierce JPM Week, is a critical event for biotech and pharma, significantly impacting San Francisco's economy.

#cancer-research

A surfer without a degree is worth $16 billion after his biotech company's stock soared 1,100% in a year

Bob Duggan, an uneducated entrepreneur, became a biotech billionaire through Summit Therapeutics, exemplifying success outside traditional academic pathways.

Bay Area biotech firm once worth $2.3 billion lays off 40% of staff

CytomX Therapeutics is laying off 40% of its staff to focus on clinical programs and improve financial flexibility.

A surfer without a degree is worth $16 billion after his biotech company's stock soared 1,100% in a year

Bob Duggan, an uneducated entrepreneur, became a biotech billionaire through Summit Therapeutics, exemplifying success outside traditional academic pathways.

Bay Area biotech firm once worth $2.3 billion lays off 40% of staff

CytomX Therapeutics is laying off 40% of its staff to focus on clinical programs and improve financial flexibility.

morecancer-research

Why a silly-sounding name suits the serious mission of our biotech spin-off

Richard Kuo's journey from a genomics PhD student to CEO of Wobble Genomics illustrates the growth potential in biotech entrepreneurship.

The aftermath of Theranos's failure has made biotech funding riskier, impacting new startups' abilities to secure investments.

What went wrong for 23andMe

23andMe is restructuring to address challenges following a $30 million data settlement and restore customer trust.

Amsterdam's 819 Capital Partners acquires Dutch biotech startup CiMaas

819 Capital Partners acquires CiMaas to enhance development of Natural Killer cell therapies for cancer treatments post-bankruptcy.

#ai-in-healthcare

Heart disease is the world's biggest killer - this Cambridge Uni spinout is using AI to find new treatments | TechCrunch

AI is transforming drug discovery, particularly for cardiovascular diseases.

CardiaTec raised $6.5 million to enhance cardiovascular disease treatments through AI.

CVDs cause 17.9 million deaths annually, highlighting a major health crisis.

Biolevate's raises 6M to helps medical writers keep up with the pace of new drugs | TechCrunch

Biolevate's platform uses AI to enhance the efficiency of medical document writing, addressing a significant lag in the biotech sector.

Heart disease is the world's biggest killer - this Cambridge Uni spinout is using AI to find new treatments | TechCrunch

AI is transforming drug discovery, particularly for cardiovascular diseases.

CardiaTec raised $6.5 million to enhance cardiovascular disease treatments through AI.

CVDs cause 17.9 million deaths annually, highlighting a major health crisis.

Biolevate's raises 6M to helps medical writers keep up with the pace of new drugs | TechCrunch

Biolevate's platform uses AI to enhance the efficiency of medical document writing, addressing a significant lag in the biotech sector.

moreai-in-healthcare

Everything to know about Vivek Ramaswamy, co-lead of the Department of Government Efficiency with Elon Musk

Vivek Ramaswamy's transition from a failed presidential bid to a key position in Trump's government highlights his rapid ascent in political influence.

#ai

Arzeda is using AI to design proteins for artificial sweeteners and more | TechCrunch

AI is revolutionizing protein design, enabling the creation of sustainable alternatives for various products.

Arzeda leverages proprietary data and advanced AI techniques to transition from research to commercial application.

SoftBank forms AI healthcare JV in Japan with Tempus | TechCrunch

SoftBank Group and Tempus form joint venture in Japan to develop AI-powered personalized medical services, starting with oncology.

Archon emerges from stealth with $20M and 'antibody cages' to power up drug development | TechCrunch

Archon Biosciences aims to revolutionize antibody treatments through innovative protein 'cages' that improve drug binding and efficacy.

Arzeda is using AI to design proteins for artificial sweeteners and more | TechCrunch

AI is revolutionizing protein design, enabling the creation of sustainable alternatives for various products.

Arzeda leverages proprietary data and advanced AI techniques to transition from research to commercial application.

SoftBank forms AI healthcare JV in Japan with Tempus | TechCrunch

SoftBank Group and Tempus form joint venture in Japan to develop AI-powered personalized medical services, starting with oncology.

Archon emerges from stealth with $20M and 'antibody cages' to power up drug development | TechCrunch

Archon Biosciences aims to revolutionize antibody treatments through innovative protein 'cages' that improve drug binding and efficacy.

moreai

Other Barks & Bites for Friday, October 18: OpenAI Outlines Defensive Patent Strategy; Microsoft Files Opposition in Lawsuit Alleging Illegal Buyer's Cartel for Patent Licenses; Moderna Under Fire for Spikevax Vaccine Tech

Trilobio wins injunction in a trade secret case against a former employee, underscoring the importance of IP protection in biotech.

Exclusive: Connected fitness startup EGYM is ramping up with $200m at a $1.2B+ valuation

EGYM secures over $200 million funding to expand tech-driven fitness solutions in new markets and enhance AI-based training tools.

#penny-stocks

3 Penny Stocks To Buy With Just $750

Penny stocks can yield high returns but involve significant risk; focus on biotech for multiple catalysts.

Investing in biotech penny stocks offers more potential due to their development timelines and regulatory advancements.

3 Penny Stocks To Buy With Just $50

Investing in penny stocks can yield high returns, but risks must be carefully managed.

3 Penny Stocks To Buy With Just $750

Penny stocks can yield high returns but involve significant risk; focus on biotech for multiple catalysts.

Investing in biotech penny stocks offers more potential due to their development timelines and regulatory advancements.

3 Penny Stocks To Buy With Just $50

Investing in penny stocks can yield high returns, but risks must be carefully managed.

morepenny-stocks

Exclusive: Synex founder, once detained at the border with a 80-pound magnet, is building portable MRIs to test glucose

Synex Medical is developing a portable MRI for non-invasive glucose testing, potentially revolutionizing diabetes care.

Lyon-based Brenus Pharma secures 22.2M to advance cancer vaccine trials: Here's how - Silicon Canals

Brenus Pharma secures €22.2M Series A funding to advance cancer vaccine development, targeting metastatic colorectal cancer and expanding into other gastric tumors.

A newly built office tower in downtown Durham is turning to speculative lab space

Developers are adapting to increased vacancy rates by creating lab space to attract tenants.

Roxboro's speculative lab spaces aim to support smaller biotech firms amidst leasing challenges.

Building a culture of GxP excellence in biotech - London Business News | Londonlovesbusiness.com

GxP is essential not only for compliance but for embedding product safety and public trust into the core operations of biotech organizations.

Tech and biotech layoffs jolt Bay Area with hundreds of lost jobs

The ongoing layoffs in Bay Area tech and biotech sectors reflect a troubling trend, with over 45,700 jobs cut since 2022.

Feds are still sending 'mad scientist' millions to China - and keeping it from Congress

The U.S. continues to fund risky research in adversarial countries, raising significant national security concerns.

#drug-discovery

Recursion to merge with Exscientia - Silicon Canals

The merger between Recursion and Exscientia aims to combine their expertise to accelerate drug design and development.

Xaira, an AI drug discovery startup, launches with a massive $1B, says it's 'ready' to start developing drugs | TechCrunch

Biotech investors tap into generative AI for drug discovery.

Recursion to merge with Exscientia - Silicon Canals

The merger between Recursion and Exscientia aims to combine their expertise to accelerate drug design and development.

Xaira, an AI drug discovery startup, launches with a massive $1B, says it's 'ready' to start developing drugs | TechCrunch

Biotech investors tap into generative AI for drug discovery.

moredrug-discovery

The AlleyWatch Startup Daily Funding Report: 5/29/2024

Gameto raised $33M in Series B funding for women's reproductive health and infertility.

COVID-19 test maker Cue Health once worth $2.3B lays off entire company and shuts down

Cue Health, a San Diego biotech firm supplying COVID-19 test kits, shut down due to FDA warning on false results, resulting in employee layoffs.

Machine Learning for Biotech, Biopharma, and ML Safety Sessions Coming to ODSC East 2024

Machine learning is crucial in safety, security, biotech, and pharma industries at ODSC East 2024.

San Jose tech and biotech incubator hub gains traction and tenants

BioCube in San Jose attracts tech and biotech companies, provides a complete ecosystem for startups to grow in place.

How gene-therapy treated mice in space may help shape the science of vision loss diseases

Biotech Oculogenex received FDA endorsement for therapy in treating eye-wasting disease.

Enveda raises $55M to combine ancient remedies with AI for drug discovery | TechCrunch

Modern pharmaceuticals have roots in natural remedies used by ancestors.

AI can expedite the process of discovering new medicines from nature.

[ Load more ]

#biotech#biotech

Bay Area biotech company, once worth $1.2 billion, lays off almost entire staff

Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views

Stocks making the biggest moves premarket: Amazon, Apple, Atlassian and more

Warren Buffett Back for More, Plus Big Insider Buying at Biotechs Too

Bay Area biotech firm guts staff, shuts trial after dangerous side effects

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Bay Area biotech company, once worth $1.2 billion, lays off almost entire staff

Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views

Stocks making the biggest moves premarket: Amazon, Apple, Atlassian and more

Warren Buffett Back for More, Plus Big Insider Buying at Biotechs Too

Bay Area biotech firm guts staff, shuts trial after dangerous side effects

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

23andMe is filing for bankruptcy. Here's what it means for your genetic data

Bay Area tech CEO resigns to bid for own flailing company

What went wrong at 23andMe? Why the genetic-data giant risks collapse

23andMe is filing for bankruptcy. Here's what it means for your genetic data

Bay Area tech CEO resigns to bid for own flailing company

What went wrong at 23andMe? Why the genetic-data giant risks collapse

#NYCtech Week in Review: 8/18/24 - 8/24/24

#NYCtech Week in Review: 5/26/24 - 6/1/24

Unleased lab space. Plunging valuations. Layoffs. In Massachusetts, the biotech slump is taking its toll.

Prolific Machines, with a $55M Series B, shines 'light' on a better way to grow lab proteins for food and medicine | TechCrunch

Visibuilt Raises 1.3 Million to Transform Asphalt Production with Mycelium

Many scientists are neurodivergent. Architects are finally starting to build labs designed for them

#NYCtech Week in Review: 8/18/24 - 8/24/24

#NYCtech Week in Review: 5/26/24 - 6/1/24

Unleased lab space. Plunging valuations. Layoffs. In Massachusetts, the biotech slump is taking its toll.

Prolific Machines, with a $55M Series B, shines 'light' on a better way to grow lab proteins for food and medicine | TechCrunch

Visibuilt Raises 1.3 Million to Transform Asphalt Production with Mycelium

Many scientists are neurodivergent. Architects are finally starting to build labs designed for them

Bay Area biotech company once worth $2B guts staff, departing execs get $600K

Bay Area biotech giant to lay off hundreds after $1.8 billion loss

Bay Area biotech firm once worth $13B lays off all but 15 workers

Calif. biotech company once worth $476M lays off every remaining employee

Bay Area biotech company lays off staff over sudden Trump administration order

Struggling Bay Area biotech firm, once worth $1B, lays off almost entire staff

Bay Area biotech company once worth $2B guts staff, departing execs get $600K

Bay Area biotech giant to lay off hundreds after $1.8 billion loss

Bay Area biotech firm once worth $13B lays off all but 15 workers

Calif. biotech company once worth $476M lays off every remaining employee

Bay Area biotech company lays off staff over sudden Trump administration order

Struggling Bay Area biotech firm, once worth $1B, lays off almost entire staff

Cradle builds out its protein-design AI platform (and wet lab) with $73M in new funding | TechCrunch

Hollywood's Olivia Wilde launches a VC firm | TechCrunch

Biotech startup Cradle raises $73 million in investment round

AstraZeneca to invest $2.5bn in drugs research and manfacturing in Beijing

Dutch immunotherapy company Pan Cancer T bags 4.2M - Silicon Canals

Cradle builds out its protein-design AI platform (and wet lab) with $73M in new funding | TechCrunch

Hollywood's Olivia Wilde launches a VC firm | TechCrunch

Biotech startup Cradle raises $73 million in investment round

AstraZeneca to invest $2.5bn in drugs research and manfacturing in Beijing

Dutch immunotherapy company Pan Cancer T bags 4.2M - Silicon Canals

Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks

Dutch biotech startup Cortalix secures 1M

NIH funding uncertainty spurs new biotech venture fund | TechCrunch

How Can Startups Navigate the Difficult Funding Environment - MedCity News

Barcelona's Zymvol secures 3M: CEO Maria Fatima Lucas on democratising enzyme development, market expansion, and more - Silicon Canals

Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy

Triveni Bio Raises $115M Series B Financing to Advance Antibody Treatments for I&I Disorders

Dutch biotech startup Cortalix secures 1M

NIH funding uncertainty spurs new biotech venture fund | TechCrunch

How Can Startups Navigate the Difficult Funding Environment - MedCity News

Barcelona's Zymvol secures 3M: CEO Maria Fatima Lucas on democratising enzyme development, market expansion, and more - Silicon Canals

Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy

Triveni Bio Raises $115M Series B Financing to Advance Antibody Treatments for I&I Disorders

Amsterdam's biotech firm Photanol files for bankruptcy

Biotechs Highlight 6 Stocks Insiders Are Buying Now

Prediction: This Will Be the Best-Performing Growth Stock Over the Next 5 Years

Biotechs Highlight 6 Stocks Insiders Are Buying Now

Prediction: This Will Be the Best-Performing Growth Stock Over the Next 5 Years

How automotive exec Crystal Brown founded CircNova, an AI drug discovery biotech | TechCrunch

'Where we are today in biology AI is similar to GPT in 2020': An interview with the CEO of Africa's biggest AI startup | TechCrunch

How automotive exec Crystal Brown founded CircNova, an AI drug discovery biotech | TechCrunch

'Where we are today in biology AI is similar to GPT in 2020': An interview with the CEO of Africa's biggest AI startup | TechCrunch

Bay Area biotech company that raised $66 million shuts down

Leiden-based biotech company ProQR bags 7.7M

Bay Area biotech company that raised $66 million shuts down

Leiden-based biotech company ProQR bags 7.7M

Skinny jabs' are turning slimmers teetotal and drinks companies are feeling the loss

#biotech
#biotech